COVID-19 e rastreamento do câncer de mama no Brasil: uma análise comparativa dos períodos pré-pandêmico e pandêmico

Resumo Objetivou-se avaliar os impactos da COVID-19 no rastreamento do câncer de mama no Brasil. Coletaram-se dados do Sistema de Informações Ambulatoriais referentes a “mamografia bilateral para rastreamento” de janeiro/2015 a dezembro/2021. As análises foram feitas por região e para o Brasil. Calc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ciência & saude coletiva 2023-01, Vol.28 (1), p.223-230
Hauptverfasser: Furlam, Tiago de Oliveira, Gomes, Luiza Moreira, Machado, Carla Jorge
Format: Artikel
Sprache:por
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 230
container_issue 1
container_start_page 223
container_title Ciência & saude coletiva
container_volume 28
creator Furlam, Tiago de Oliveira
Gomes, Luiza Moreira
Machado, Carla Jorge
description Resumo Objetivou-se avaliar os impactos da COVID-19 no rastreamento do câncer de mama no Brasil. Coletaram-se dados do Sistema de Informações Ambulatoriais referentes a “mamografia bilateral para rastreamento” de janeiro/2015 a dezembro/2021. As análises foram feitas por região e para o Brasil. Calculou-se a média de exames em cada mês do ano com base nos dados de 2015 a 2019, a qual foi comparada, mensalmente, com o quantitativo de exames em 2020 e 2021, obtendo-se a diferença bruta e percentual entre esses valores. A mesma análise foi realizada para o número total de exames em 2020 e 2021, individualmente, e para os dois anos em conjunto. Em 2020 houve quedas no número de exames que variaram de 25% (Norte) a 48% (Nordeste), culminando em 1,749 milhão de exames a menos no país (queda de 44%). Em 2021, a região Centro-Oeste apresentou quantitativo de exames 11% superior ao esperado, enquanto as demais regiões apresentaram quedas entre 17% (Norte) e 27% (Sudeste/Sul), culminando em negativo de 927 mil exames no país (redução de 23%). Na análise conjunta (2020/2021), encontraram-se reduções que variaram de 11% (Centro-Oeste) a 35% (Sudeste/Sul), culminando em negativo de 2,676 milhões de procedimentos no Brasil (queda de 33%). Abstract The scope of this study was to evaluate the impacts of COVID-19 on breast cancer screening in Brazil. Data were collected from the Ambulatory Information System relating to “bilateral screening mammography” from January/2015 to December/2021. Analyses were performed by region and for Brazil. The average of exams in each month of the year was calculated based on 2015-2019 data, which was compared, monthly, with the number of exams in 2020 and 2021, obtaining the gross and percentage difference between these values. The same analysis was performed for the total number of exams in 2020 and 2021, individually, and for the two years combined. In 2020 there were reductions in the number of exams, which ranged from 25% (North) to 48% (Northeast), resulting in 1.749 million fewer exams than expected in the country (a drop of 44%). In 2021, the Midwest region presented a number of exams 11% higher than expected, while the other regions presented drops between 17% (North) and 27% (Southeast/South), resulting in 927 thousand exams fewer than expected in Brazil (reduction of 23%). In the joint analysis (2020/2021), reductions varied by region from 11% (Midwest) to 35% (Southeast/South), culminating in 2.676 million exams fewer than expect
doi_str_mv 10.1590/1413-81232023281.06442022
format Article
fullrecord <record><control><sourceid>proquest_sciel</sourceid><recordid>TN_cdi_scielo_journals_S1413_81232023000100223</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><scielo_id>S1413_81232023000100223</scielo_id><sourcerecordid>2818864694</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2942-13b0ec4afc19d011ea6e5194550e75dc6cefa372f916d3ef285804502bbb154c3</originalsourceid><addsrcrecordid>eNpVkdtKw0AQhoMoWKvvsOJ16s4ecvBO66lQ6IWH27DZTCAlycbdVPBx9E7Bp8iLubWW4sUw_8D_zcA_QXAKdAIypecggIcJMM6orwQmNBLCa7YXjCCKk1DICPa93voOgyPnlpSymAs2Ct6mi-fZdQgpQWKV6y2qBtvekMIQPXy0Gi0pkDSqUaQ15Mp7qvqCrPyo2uG9rhwSbZpOWdVXr8pjjnRoh2_zq-zwGXaqLYavptLG39gNx8FBqWqHJ399HDzd3jxO78P54m42vZyHmqWChcBzilqoUkNaUABUEUpIhZQUY1noSGOpeMzKFKKCY8kSmVAhKcvzHKTQfBxMNnudrrA22dKsbOsPZg_rTLJtdpRS8Kkw7oGzDdBZ87JC1-8QH3CSRCJKhXelG5e2xjmLZdbZqlH2LQOarV-T_VvvyWz7Gv4Dd-CCGw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2818864694</pqid></control><display><type>article</type><title>COVID-19 e rastreamento do câncer de mama no Brasil: uma análise comparativa dos períodos pré-pandêmico e pandêmico</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Furlam, Tiago de Oliveira ; Gomes, Luiza Moreira ; Machado, Carla Jorge</creator><creatorcontrib>Furlam, Tiago de Oliveira ; Gomes, Luiza Moreira ; Machado, Carla Jorge</creatorcontrib><description>Resumo Objetivou-se avaliar os impactos da COVID-19 no rastreamento do câncer de mama no Brasil. Coletaram-se dados do Sistema de Informações Ambulatoriais referentes a “mamografia bilateral para rastreamento” de janeiro/2015 a dezembro/2021. As análises foram feitas por região e para o Brasil. Calculou-se a média de exames em cada mês do ano com base nos dados de 2015 a 2019, a qual foi comparada, mensalmente, com o quantitativo de exames em 2020 e 2021, obtendo-se a diferença bruta e percentual entre esses valores. A mesma análise foi realizada para o número total de exames em 2020 e 2021, individualmente, e para os dois anos em conjunto. Em 2020 houve quedas no número de exames que variaram de 25% (Norte) a 48% (Nordeste), culminando em 1,749 milhão de exames a menos no país (queda de 44%). Em 2021, a região Centro-Oeste apresentou quantitativo de exames 11% superior ao esperado, enquanto as demais regiões apresentaram quedas entre 17% (Norte) e 27% (Sudeste/Sul), culminando em negativo de 927 mil exames no país (redução de 23%). Na análise conjunta (2020/2021), encontraram-se reduções que variaram de 11% (Centro-Oeste) a 35% (Sudeste/Sul), culminando em negativo de 2,676 milhões de procedimentos no Brasil (queda de 33%). Abstract The scope of this study was to evaluate the impacts of COVID-19 on breast cancer screening in Brazil. Data were collected from the Ambulatory Information System relating to “bilateral screening mammography” from January/2015 to December/2021. Analyses were performed by region and for Brazil. The average of exams in each month of the year was calculated based on 2015-2019 data, which was compared, monthly, with the number of exams in 2020 and 2021, obtaining the gross and percentage difference between these values. The same analysis was performed for the total number of exams in 2020 and 2021, individually, and for the two years combined. In 2020 there were reductions in the number of exams, which ranged from 25% (North) to 48% (Northeast), resulting in 1.749 million fewer exams than expected in the country (a drop of 44%). In 2021, the Midwest region presented a number of exams 11% higher than expected, while the other regions presented drops between 17% (North) and 27% (Southeast/South), resulting in 927 thousand exams fewer than expected in Brazil (reduction of 23%). In the joint analysis (2020/2021), reductions varied by region from 11% (Midwest) to 35% (Southeast/South), culminating in 2.676 million exams fewer than expected in Brazil (reduction of 33%).</description><identifier>ISSN: 1413-8123</identifier><identifier>ISSN: 1678-4561</identifier><identifier>EISSN: 1678-4561</identifier><identifier>DOI: 10.1590/1413-81232023281.06442022</identifier><language>por</language><publisher>Rio de Janeiro: Associação Brasileira de Saúde Coletiva</publisher><subject>Breast cancer ; Coronaviruses ; COVID-19 ; Mammography ; Medical screening ; Pandemics ; PUBLIC, ENVIRONMENTAL &amp; OCCUPATIONAL HEALTH ; Reduction</subject><ispartof>Ciência &amp; saude coletiva, 2023-01, Vol.28 (1), p.223-230</ispartof><rights>Copyright © 2023. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>This work is licensed under a Creative Commons Attribution 4.0 International License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2942-13b0ec4afc19d011ea6e5194550e75dc6cefa372f916d3ef285804502bbb154c3</citedby><cites>FETCH-LOGICAL-c2942-13b0ec4afc19d011ea6e5194550e75dc6cefa372f916d3ef285804502bbb154c3</cites><orcidid>0000-0002-6871-0709 ; 0000-0001-5426-3357 ; 0000-0001-8826-4964</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27922,27923</link.rule.ids></links><search><creatorcontrib>Furlam, Tiago de Oliveira</creatorcontrib><creatorcontrib>Gomes, Luiza Moreira</creatorcontrib><creatorcontrib>Machado, Carla Jorge</creatorcontrib><title>COVID-19 e rastreamento do câncer de mama no Brasil: uma análise comparativa dos períodos pré-pandêmico e pandêmico</title><title>Ciência &amp; saude coletiva</title><addtitle>Ciênc. saúde coletiva</addtitle><description>Resumo Objetivou-se avaliar os impactos da COVID-19 no rastreamento do câncer de mama no Brasil. Coletaram-se dados do Sistema de Informações Ambulatoriais referentes a “mamografia bilateral para rastreamento” de janeiro/2015 a dezembro/2021. As análises foram feitas por região e para o Brasil. Calculou-se a média de exames em cada mês do ano com base nos dados de 2015 a 2019, a qual foi comparada, mensalmente, com o quantitativo de exames em 2020 e 2021, obtendo-se a diferença bruta e percentual entre esses valores. A mesma análise foi realizada para o número total de exames em 2020 e 2021, individualmente, e para os dois anos em conjunto. Em 2020 houve quedas no número de exames que variaram de 25% (Norte) a 48% (Nordeste), culminando em 1,749 milhão de exames a menos no país (queda de 44%). Em 2021, a região Centro-Oeste apresentou quantitativo de exames 11% superior ao esperado, enquanto as demais regiões apresentaram quedas entre 17% (Norte) e 27% (Sudeste/Sul), culminando em negativo de 927 mil exames no país (redução de 23%). Na análise conjunta (2020/2021), encontraram-se reduções que variaram de 11% (Centro-Oeste) a 35% (Sudeste/Sul), culminando em negativo de 2,676 milhões de procedimentos no Brasil (queda de 33%). Abstract The scope of this study was to evaluate the impacts of COVID-19 on breast cancer screening in Brazil. Data were collected from the Ambulatory Information System relating to “bilateral screening mammography” from January/2015 to December/2021. Analyses were performed by region and for Brazil. The average of exams in each month of the year was calculated based on 2015-2019 data, which was compared, monthly, with the number of exams in 2020 and 2021, obtaining the gross and percentage difference between these values. The same analysis was performed for the total number of exams in 2020 and 2021, individually, and for the two years combined. In 2020 there were reductions in the number of exams, which ranged from 25% (North) to 48% (Northeast), resulting in 1.749 million fewer exams than expected in the country (a drop of 44%). In 2021, the Midwest region presented a number of exams 11% higher than expected, while the other regions presented drops between 17% (North) and 27% (Southeast/South), resulting in 927 thousand exams fewer than expected in Brazil (reduction of 23%). In the joint analysis (2020/2021), reductions varied by region from 11% (Midwest) to 35% (Southeast/South), culminating in 2.676 million exams fewer than expected in Brazil (reduction of 33%).</description><subject>Breast cancer</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Mammography</subject><subject>Medical screening</subject><subject>Pandemics</subject><subject>PUBLIC, ENVIRONMENTAL &amp; OCCUPATIONAL HEALTH</subject><subject>Reduction</subject><issn>1413-8123</issn><issn>1678-4561</issn><issn>1678-4561</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpVkdtKw0AQhoMoWKvvsOJ16s4ecvBO66lQ6IWH27DZTCAlycbdVPBx9E7Bp8iLubWW4sUw_8D_zcA_QXAKdAIypecggIcJMM6orwQmNBLCa7YXjCCKk1DICPa93voOgyPnlpSymAs2Ct6mi-fZdQgpQWKV6y2qBtvekMIQPXy0Gi0pkDSqUaQ15Mp7qvqCrPyo2uG9rhwSbZpOWdVXr8pjjnRoh2_zq-zwGXaqLYavptLG39gNx8FBqWqHJ399HDzd3jxO78P54m42vZyHmqWChcBzilqoUkNaUABUEUpIhZQUY1noSGOpeMzKFKKCY8kSmVAhKcvzHKTQfBxMNnudrrA22dKsbOsPZg_rTLJtdpRS8Kkw7oGzDdBZ87JC1-8QH3CSRCJKhXelG5e2xjmLZdbZqlH2LQOarV-T_VvvyWz7Gv4Dd-CCGw</recordid><startdate>202301</startdate><enddate>202301</enddate><creator>Furlam, Tiago de Oliveira</creator><creator>Gomes, Luiza Moreira</creator><creator>Machado, Carla Jorge</creator><general>Associação Brasileira de Saúde Coletiva</general><general>ABRASCO - Associação Brasileira de Saúde Coletiva</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>L6V</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7S</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>Q9U</scope><scope>GPN</scope><orcidid>https://orcid.org/0000-0002-6871-0709</orcidid><orcidid>https://orcid.org/0000-0001-5426-3357</orcidid><orcidid>https://orcid.org/0000-0001-8826-4964</orcidid></search><sort><creationdate>202301</creationdate><title>COVID-19 e rastreamento do câncer de mama no Brasil: uma análise comparativa dos períodos pré-pandêmico e pandêmico</title><author>Furlam, Tiago de Oliveira ; Gomes, Luiza Moreira ; Machado, Carla Jorge</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2942-13b0ec4afc19d011ea6e5194550e75dc6cefa372f916d3ef285804502bbb154c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>por</language><creationdate>2023</creationdate><topic>Breast cancer</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Mammography</topic><topic>Medical screening</topic><topic>Pandemics</topic><topic>PUBLIC, ENVIRONMENTAL &amp; OCCUPATIONAL HEALTH</topic><topic>Reduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Furlam, Tiago de Oliveira</creatorcontrib><creatorcontrib>Gomes, Luiza Moreira</creatorcontrib><creatorcontrib>Machado, Carla Jorge</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Engineering Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>ProQuest Central Basic</collection><collection>SciELO</collection><jtitle>Ciência &amp; saude coletiva</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Furlam, Tiago de Oliveira</au><au>Gomes, Luiza Moreira</au><au>Machado, Carla Jorge</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19 e rastreamento do câncer de mama no Brasil: uma análise comparativa dos períodos pré-pandêmico e pandêmico</atitle><jtitle>Ciência &amp; saude coletiva</jtitle><addtitle>Ciênc. saúde coletiva</addtitle><date>2023-01</date><risdate>2023</risdate><volume>28</volume><issue>1</issue><spage>223</spage><epage>230</epage><pages>223-230</pages><issn>1413-8123</issn><issn>1678-4561</issn><eissn>1678-4561</eissn><abstract>Resumo Objetivou-se avaliar os impactos da COVID-19 no rastreamento do câncer de mama no Brasil. Coletaram-se dados do Sistema de Informações Ambulatoriais referentes a “mamografia bilateral para rastreamento” de janeiro/2015 a dezembro/2021. As análises foram feitas por região e para o Brasil. Calculou-se a média de exames em cada mês do ano com base nos dados de 2015 a 2019, a qual foi comparada, mensalmente, com o quantitativo de exames em 2020 e 2021, obtendo-se a diferença bruta e percentual entre esses valores. A mesma análise foi realizada para o número total de exames em 2020 e 2021, individualmente, e para os dois anos em conjunto. Em 2020 houve quedas no número de exames que variaram de 25% (Norte) a 48% (Nordeste), culminando em 1,749 milhão de exames a menos no país (queda de 44%). Em 2021, a região Centro-Oeste apresentou quantitativo de exames 11% superior ao esperado, enquanto as demais regiões apresentaram quedas entre 17% (Norte) e 27% (Sudeste/Sul), culminando em negativo de 927 mil exames no país (redução de 23%). Na análise conjunta (2020/2021), encontraram-se reduções que variaram de 11% (Centro-Oeste) a 35% (Sudeste/Sul), culminando em negativo de 2,676 milhões de procedimentos no Brasil (queda de 33%). Abstract The scope of this study was to evaluate the impacts of COVID-19 on breast cancer screening in Brazil. Data were collected from the Ambulatory Information System relating to “bilateral screening mammography” from January/2015 to December/2021. Analyses were performed by region and for Brazil. The average of exams in each month of the year was calculated based on 2015-2019 data, which was compared, monthly, with the number of exams in 2020 and 2021, obtaining the gross and percentage difference between these values. The same analysis was performed for the total number of exams in 2020 and 2021, individually, and for the two years combined. In 2020 there were reductions in the number of exams, which ranged from 25% (North) to 48% (Northeast), resulting in 1.749 million fewer exams than expected in the country (a drop of 44%). In 2021, the Midwest region presented a number of exams 11% higher than expected, while the other regions presented drops between 17% (North) and 27% (Southeast/South), resulting in 927 thousand exams fewer than expected in Brazil (reduction of 23%). In the joint analysis (2020/2021), reductions varied by region from 11% (Midwest) to 35% (Southeast/South), culminating in 2.676 million exams fewer than expected in Brazil (reduction of 33%).</abstract><cop>Rio de Janeiro</cop><pub>Associação Brasileira de Saúde Coletiva</pub><doi>10.1590/1413-81232023281.06442022</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-6871-0709</orcidid><orcidid>https://orcid.org/0000-0001-5426-3357</orcidid><orcidid>https://orcid.org/0000-0001-8826-4964</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1413-8123
ispartof Ciência & saude coletiva, 2023-01, Vol.28 (1), p.223-230
issn 1413-8123
1678-4561
1678-4561
language por
recordid cdi_scielo_journals_S1413_81232023000100223
source EZB-FREE-00999 freely available EZB journals
subjects Breast cancer
Coronaviruses
COVID-19
Mammography
Medical screening
Pandemics
PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Reduction
title COVID-19 e rastreamento do câncer de mama no Brasil: uma análise comparativa dos períodos pré-pandêmico e pandêmico
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A00%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_sciel&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19%20e%20rastreamento%20do%20c%C3%A2ncer%20de%20mama%20no%20Brasil:%20uma%20an%C3%A1lise%20comparativa%20dos%20per%C3%ADodos%20pr%C3%A9-pand%C3%AAmico%20e%20pand%C3%AAmico&rft.jtitle=Ci%C3%AAncia%20&%20saude%20coletiva&rft.au=Furlam,%20Tiago%20de%20Oliveira&rft.date=2023-01&rft.volume=28&rft.issue=1&rft.spage=223&rft.epage=230&rft.pages=223-230&rft.issn=1413-8123&rft.eissn=1678-4561&rft_id=info:doi/10.1590/1413-81232023281.06442022&rft_dat=%3Cproquest_sciel%3E2818864694%3C/proquest_sciel%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2818864694&rft_id=info:pmid/&rft_scielo_id=S1413_81232023000100223&rfr_iscdi=true